The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Foscavir     phosphonomethanoic acid

Synonyms: Triapten, Foscarmet, Virudin, foscarnet, CHEMBL666, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of phosphonoformic acid


Psychiatry related information on phosphonoformic acid

  • Increased liver enzymes, hallucinations and tremor were seen in one uraemic patient and coincided with foscarnet plasma concentrations above 400 mg/l. Among 25 patients evaluated for clinical efficacy, 12 died [6].
  • CASE REPORT: A 2-years-old male infant was referred to our department with a history of Epstein-Barr virus (EBV) encephalitis, treated with foscarnet and steroids, for he developed mutism and ataxia and loss of the ability to eat, walk and talk [7].

High impact information on phosphonoformic acid


Chemical compound and disease context of phosphonoformic acid


Biological context of phosphonoformic acid


Anatomical context of phosphonoformic acid


Associations of phosphonoformic acid with other chemical compounds


Gene context of phosphonoformic acid


Analytical, diagnostic and therapeutic context of phosphonoformic acid


  1. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. Chatis, P.A., Miller, C.H., Schrager, L.E., Crumpacker, C.S. N. Engl. J. Med. (1989) [Pubmed]
  2. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. Safrin, S., Crumpacker, C., Chatis, P., Davis, R., Hafner, R., Rush, J., Kessler, H.A., Landry, B., Mills, J. N. Engl. J. Med. (1991) [Pubmed]
  3. Foscarnet for CMV retinitis. Wood, C.A. Lancet (1992) [Pubmed]
  4. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Sandstrom, E.G., Kaplan, J.C., Byington, R.E., Hirsch, M.S. Lancet (1985) [Pubmed]
  5. Foscarnet in fulminant hepatitis B. Price, J.S., France, A.J., Moaven, L.D., Welsby, P.D. Lancet (1986) [Pubmed]
  6. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. Ringdén, O., Lönnqvist, B., Paulin, T., Ahlmén, J., Klintmalm, G., Wahren, B., Lernestedt, J.O. J. Antimicrob. Chemother. (1986) [Pubmed]
  7. Transcranial magnetic stimulation. A case report and review of the literature. Anninos, P., Kotini, A., Tamiolakis, D., Tsagas, N. Acta neurologica Belgica. (2006) [Pubmed]
  8. Trisodium phosphonoformate, a new antiviral compound. Helgstrand, E., Eriksson, B., Johansson, N.G., Lannerö, B., Larsson, A., Misiorny, A., Norén, J.O., Sjöberg, B., Stenberg, K., Stening, G., Stridh, S., Oberg, B. Science (1978) [Pubmed]
  9. Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. Mesri, E.A., Cesarman, E., Arvanitakis, L., Rafii, S., Moore, M.A., Posnett, D.N., Knowles, D.M., Asch, A.S. J. Exp. Med. (1996) [Pubmed]
  10. Regulation of sodium-dependent phosphate transport in osteoclasts. Gupta, A., Guo, X.L., Alvarez, U.M., Hruska, K.A. J. Clin. Invest. (1997) [Pubmed]
  11. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Palestine, A.G., Polis, M.A., De Smet, M.D., Baird, B.F., Falloon, J., Kovacs, J.A., Davey, R.T., Zurlo, J.J., Zunich, K.M., Davis, M. Ann. Intern. Med. (1991) [Pubmed]
  12. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Lalezari, J.P., Stagg, R.J., Kuppermann, B.D., Holland, G.N., Kramer, F., Ives, D.V., Youle, M., Robinson, M.R., Drew, W.L., Jaffe, H.S. Ann. Intern. Med. (1997) [Pubmed]
  13. Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child. Stránská, R., van Loon, A.M., Bredius, R.G., Polman, M., Nienhuis, E., Beersma, M.F., Lankester, A.C., Schuurman, R. Antivir. Ther. (Lond.) (2004) [Pubmed]
  14. Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase. Arion, D., Sluis-Cremer, N., Parniak, M.A. J. Biol. Chem. (2000) [Pubmed]
  15. Role of the progressive ankylosis gene (ank) in cartilage mineralization. Wang, W., Xu, J., Du, B., Kirsch, T. Mol. Cell. Biol. (2005) [Pubmed]
  16. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Klass, C.M., Krug, L.T., Pozharskaya, V.P., Offermann, M.K. Blood (2005) [Pubmed]
  17. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Strahl, C., Blackburn, E.H. Mol. Cell. Biol. (1996) [Pubmed]
  18. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. Canestri, A., Ghosn, J., Wirden, M., Marguet, F., Ktorza, N., Boubezari, I., Dominguez, S., Bossi, P., Caumes, E., Calvez, V., Katlama, C. Antivir. Ther. (Lond.) (2006) [Pubmed]
  19. Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine. Foster, S.A., Cerny, J., Cheng, Y.C. J. Biol. Chem. (1991) [Pubmed]
  20. In vitro effect of foscarnet on expansion of T-cells from people with LAS and AIDS. Beldekas, J.C., Levy, E.M., Black, P., Von Krogh, G., Sandstrom, E. Lancet (1985) [Pubmed]
  21. Uvula and oesophageal ulcerations with foscarnet. Saint-Marc, T., Fournier, F., Touraine, J.L., Marneff, E. Lancet (1992) [Pubmed]
  22. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Reusser, P., Einsele, H., Lee, J., Volin, L., Rovira, M., Engelhard, D., Finke, J., Cordonnier, C., Link, H., Ljungman, P. Blood (2002) [Pubmed]
  23. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Eckle, T., Prix, L., Jahn, G., Klingebiel, T., Handgretinger, R., Selle, B., Hamprecht, K. Blood (2000) [Pubmed]
  24. Susceptibility of human cytomegalovirus to two-drug combinations in vitro. Manion, D.J., Vibhagool, A., Chou, T.C., Kaplan, J., Caliendo, A., Hirsch, M.S. Antivir. Ther. (Lond.) (1996) [Pubmed]
  25. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. Sardana, V.V., Emini, E.A., Gotlib, L., Graham, D.J., Lineberger, D.W., Long, W.J., Schlabach, A.J., Wolfgang, J.A., Condra, J.H. J. Biol. Chem. (1992) [Pubmed]
  26. Phosphonocarboxylic acids as specific inhibitors of Na+-dependent transport of phosphate across renal brush border membrane. Szczepanska-Konkel, M., Yusufi, A.N., VanScoy, M., Webster, S.K., Dousa, T.P. J. Biol. Chem. (1986) [Pubmed]
  27. Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. Spector, S.A., Tyndall, M., Kelley, E. Am. J. Med. (1982) [Pubmed]
  28. Role of interleukin-8 in PiT-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. Cecil, D.L., Rose, D.M., Terkeltaub, R., Liu-Bryan, R. Arthritis Rheum. (2005) [Pubmed]
  29. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. Chou, S., Marousek, G., Parenti, D.M., Gordon, S.M., LaVoy, A.G., Ross, J.G., Miner, R.C., Drew, W.L. J. Infect. Dis. (1998) [Pubmed]
  30. Requirement of calcium and phosphate ions in expression of sodium-dependent vitamin C transporter 2 and osteopontin in MC3T3-E1 osteoblastic cells. Wu, X., Itoh, N., Taniguchi, T., Nakanishi, T., Tanaka, K. Biochim. Biophys. Acta (2003) [Pubmed]
  31. Declining levels of HIV P24 antigen in serum during treatment with foscarnet. Bergdahl, S., Sönnerborg, A., Larsson, A., Strannegard, O. Lancet (1988) [Pubmed]
  32. Inflammatory cells in transplanted kidneys are infected by human cytomegalovirus. Gnann, J.W., Ahlmén, J., Svalander, C., Olding, L., Oldstone, M.B., Nelson, J.A. Am. J. Pathol. (1988) [Pubmed]
  33. A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet. Seidel, E.A., Koenig, S., Polis, M.A. AIDS (1993) [Pubmed]
  34. Rapid progression of HIV disease in children with cytomegalovirus DNAemia. Nigro, G., Krzysztofiak, A., Gattinara, G.C., Mango, T., Mazzocco, M., Porcaro, M.A., Provvedi, S., Booth, J.C. AIDS (1996) [Pubmed]
  35. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. Aweeka, F.T., Gambertoglio, J.G., Kramer, F., van der Horst, C., Polsky, B., Jayewardene, A., Lizak, P., Emrick, L., Tong, W., Jacobson, M.A. Clin. Pharmacol. Ther. (1995) [Pubmed]
WikiGenes - Universities